Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems by Kaufmann, Carole P. et al.
1Kaufmann CP, et al. BMJ Open 2018;8:e016610. doi:10.1136/bmjopen-2017-016610
Open Access 
Drug-Associated Risk Tool: 
development and validation of a self-
assessment questionnaire to screen for 
hospitalised patients at risk for drug-
related problems
Carole P Kaufmann,1 Dominik Stämpfli,1 Nadine Mory,1 Kurt E Hersberger,1 
Markus L Lampert1,2
To cite: Kaufmann CP, 
Stämpfli D, Mory N, et al.  
Drug-Associated Risk Tool: 
development and validation of a 
self-assessment questionnaire 
to screen for hospitalised 
patients at risk for drug-
related problems. BMJ Open 
2018;8:e016610. doi:10.1136/
bmjopen-2017-016610
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
016610).
CPK and DS contributed equally.
Received 24 February 2017
Revised 4 August 2017
Accepted 8 August 2017
1Pharmaceutical Care 
Research Group, Department 
of Pharmaceutical Sciences, 
University of Basel, Basel, 
Switzerland
2Institute of Hospital Pharmacy, 
Solothurner Spitäler, Olten, 
Switzerland
Correspondence to
Dr Markus L Lampert;  
 markus. lampert@ unibas. ch
Research
AbstrACt
Introduction Identifying patients with a high risk for drug-
related problems (DRPs) might optimise the allocation of 
targeted pharmaceutical care during the hospital stay and 
on discharge.
Objective To develop a self-assessment screening tool 
to identify patients at risk for DRPs and validate the tool 
regarding feasibility, acceptability and the reliability of the 
patients’ answers.
Design Prospective validation study.
setting Two mid-sized hospitals (300–400 beds).
Participants 195 patients, exclusion criteria: under 18 
years old, patients with a health status not allowing a 
meaningful communication (eg, delirium, acute psychosis, 
advanced dementia, aphasia, clouded consciousness 
state), palliative or terminally ill patients.
Methods Twenty-seven risk factors for the development 
of DRPs, identified in a previous study, provided the basis 
of the self-assessment questionnaire, the Drug-Associated 
Risk Tool (DART). Consenting patients filled in DART, and 
we compared their answers with objective patient data 
from medical records and laboratory data.
results One hundred and sixty-four patients filled in DART 
V.1.0 in an average time of 7 min. After a first validation, we 
identified statements with a low sensitivity and revised the 
wording of the questions related to heart insufficiency, renal 
impairment or liver impairment. The revised DART (V.2.0) 
was validated in 31 patients presenting heart insufficiency, 
renal impairment or liver impairment as comorbidity and 
reached an average specificity of 88% (range 27–100) and 
an average sensitivity of 67% (range 21–100).
Conclusions DART showed a satisfying feasibility and 
reliability. The specificity of the statements was mostly 
high. The sensitivity varied and was higher in statements 
concerning diseases that require regular disease control 
and attention to self-care and drug management. Asking 
patients about their conditions, medications and related 
problems can facilitate getting a first, broad picture of the 
risk for DRPs and possible pharmaceutical needs.
IntrODuCtIOn 
Drug-related problems (DRPs) are defined 
as an event or circumstance involving drug 
therapy that actually or potentially interferes 
with desired health outcomes.1 The term 
‘DRPs’ has mostly taken hold in European 
countries where English is not the native 
language, while pharmacists in the USA tend 
to use the term ‘medicine-related problems’ 
or ‘drug-therapy problems’ instead of DRPs.2 
DRPs are a frequent issue among hospital-
ised patients, leading to patient harm and 
increased healthcare costs.3 Many unplanned 
admissions are medication related4 and a 
considerable number could be prevented.5 
Complexity and often poorly designed 
processes foster the development of DRPs 
inside and outside of the hospital. Unsurpris-
ingly, a remarkable number of patients expe-
rience adverse drug events after discharge.6 
A study from Switzerland showed that 36% 
of all discharge prescriptions contained tech-
nical DRPs like unreadable prescriptions, 
missing drug form and package size, and 
strengths and limitations of this study
 ► The Drug-Associated Risk Tool (DART) is a patient 
self-assessment risk screening tool, based on a 
selection of risk factors for the development of drug-
related problems  (DRPs), previously identified in a 
combination of literature search and the opinion of a 
multidisciplinary expert panel.
 ► DART should enable clinical pharmacists to identify 
patients at risk for DRPs and target their clinical 
pharmacy activities to patients who benefit the most 
thereof.
 ► A first validation of DART showed good acceptability 
and feasibility and a satisfactory reliability of 
patient’s answers.
 ► The low prevalence of some risk factors hinders 
clear conclusions about the validity of the respective 
statements in DART.
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19.6% showed clinical DRPs like drug–drug interactions, 
inappropriate drug choice and wrong dosing.7
Clinical pharmacy services in hospitals have been shown 
to increase patient safety by reducing medication errors 
and adverse drug events, as well as adverse drug reactions. 
They increase medication appropriateness, improve 
patients’ knowledge about drug therapy and adherence, 
and finally reduce the length of hospital stays.8 Limited 
resources and capacities force clinical pharmacists to 
target their clinical activities to those patients who are most 
likely to benefit therefrom, or in other words, to those 
patients who are at the highest risk of experiencing DRPs, 
and in consequence, adverse drug events. An effective 
screening tool to identify high-risk patients might prove 
a successful approach. The literature provides risk factors 
for the development of DRPs such as polypharmacy, renal 
impairment or the use of non-steroidal anti-inflammatory 
drugs .4 9 10 The literature is replete with assessment tools, 
which focus on various combinations of risk factors for 
DRPs. They may be created either for a specific group 
of patients (eg, those with renal impairment,11 geriatric 
patients,12–16 patients with prescribed medication for 
cardiovascular disease17) or for a special environment 
(eg, in an emergency department,18 primary care19 20). 
The tools may also need special resources to be applied in 
the hospital (eg, computerised patient files21). Screening 
tools often have the disadvantage of being time and 
personnel intensive; some are hardly applicable without 
electronic data. Many have not been validated.22
Therefore, we decided to develop a new risk assessment 
tool. The ‘Drug-Associated Risk Tool (DART)’ should 
serve as a reliable, easy-to-use screening instrument to 
detect patients at risk for DRPs. Developed as a self-assess-
ment questionnaire for the patients, DART should save 
personnel resources and time.
In a previous study,23 we identified 27 risk factors for 
the development of DRPs, which provided the basis of the 
self-assessment questionnaire. Risk factors identified in 
relevant literature were supplemented with results from 
qualitative research methods: We conducted a Nominal 
Group Technique with practitioners to ensure relevance 
in everyday practice and to identify risk factors possibly 
neglected in quantitative research methods.
The aim of this study was to create a self-assessment ques-
tionnaire out of the identified risk factors and to validate 
the questionnaire regarding feasibility, acceptability and 
the reliability of the patients’ answers by comparing them 
to reference information retrieved from medical charts.
MethODs
Development of the questionnaire
Figure 1 shows the development process of the 
questionnaire.
Twenty-seven risk factors for the development of DRPs, 
identified in a previous study,23 provided the basis of the 
self-assessment questionnaire, DART. With the intention 
of creating a questionnaire for patients, we formulated a 
statement for each risk factor that could be answered by 
medical laypersons (cf. table 1).
We covered the risk factor ‘non-adherence’ with an 
adapted question retrieved from the adherence risk 
prediction tool of Krousel-Wood,24 a validated self-re-
port 4-item questionnaire used to measure adherence. 
A validated self-report four-item questionnaire used to 
measure adherence. Risk factors with regard to patients’ 
concerns about medicines were covered by using five 
questions from the Beliefs about Medicines Question-
naire (BMQ),25 a questionnaire that comprises two five-
item scales assessing patients’ opinions about the necessity 
of prescribed medication for controlling their illness and 
their concerns about the potential adverse consequences 
of taking it.
Amateur test
Prior to the study, we conducted an amateur test and 
asked 10 medical laypersons from the personal environ-
ment of the authors (no patients) to fill out DART. We 
did not provide any support during its completion. We 
asked the participants for their judgement concerning 
the comprehensibility of the statements and edited issues 
that arose within the statements. In cases of ambiguity, 
the study investigators (CPK, MLL, NM, DS) discussed 
and clarified the unclear statements.
Validation of the questionnaire
Study design and setting
For the prospective validation study, we recruited patients 
in two mid-sized hospitals with 300–400 beds each. 
We recruited on orthopaedic, geriatric and internal 
Figure 1 Development process of the questionnaire. BMQ, Beliefs about Medicines Questionnaire; DART, Drug-Associated 
Risk Tool; DRP, drug-related problem; MMT, Micro-Mental Test; NGT, nominal group technique.
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medicine wards in order to validate the questionnaire in 
very diverse patients.
Patient selection
Eligibility criteria were stationary hospitalisation, age over 
18 years and ability to speak German in order to commu-
nicate with the investigator. We excluded patients with 
a health status not allowing a meaningful communica-
tion (eg, delirium, acute psychosis, advanced dementia, 
aphasia, clouded consciousness state) as well as palliative 
or terminally ill patients. We included patients suffering 
from mild dementia in case a meaningful communica-
tion was possible.
Study flow
During a predefined period, the investigators (CPK, DS, 
NM) and two additional trained clinical pharmacists met 
with every hospitalised patient on the included wards 
who met the inclusion criteria. They informed each 
patient orally and with an informational letter about 
the study. After giving informed consent, the patient 
received DART and filled in the questionnaire inde-
pendently, that is, the investigator gave no assistance in 
filling in the questionnaire. If a patient had impaired 
manual skills, the investigator was only allowed to assist 
with writing. When finished, the investigator asked the 
patient five questions about the structure and content 
Table 1 Risk factors, their corresponding statement in the Drug-Associated Risk Tool (DART) and criteria to evaluate 
correlation between the answers in DART and objective data
Risk factor
Corresponding 
statement 
in DART Acceptance criteria for correlation
Language issues (eg, migration background) 1 No comparison with objective data
Polymorbidity: divided in subcategories
  Renal impairment 2 Diagnosis of renal impairment and/or GFR <60 mL/min for at 
least 3 months33
  Hepatic impairment 3 Diagnosis of hepatic impairment and/or chronic hepatitis 
and/or hepatic cirrhosis
  Chronic cardiac disease 4 Diagnosis of chronic cardiac disease (heart failure, coronary 
heart disease, arrhythmias)
  Chronic respiratory disease 5 Diagnosis of asthma or chronic obstructive pulmonary 
disease
  Diabetes 6 Diagnosis of diabetes mellitus type 1 or 2 or diabetes 
caused by steroids
  Cognitive impairment/dementia 7 Diagnosis of cognitive impairment or dementia or 25/30 
points in the Mini-Mental State Examination34 or <14/20 
points in the Micro-Mental Test26
The patient takes medication(s) besides the prescribed 
ones (eg, over-the-counter, vitamin supplementation)
8 No comparison with objective data possible
Polypharmacy 9 The patient takes more than five medicines when admitted 
to the hospital
Antiepileptic, anticoagulants, non-steroidal anti-
inflammatory drugs (NSAIDs), combination of NSAIDs 
and anticoagulants, digoxin, corticosteroids, diuretics, 
tricyclic antidepressants, anticholinergic drugs, 
benzodiazepines, opiates/opioids, oral antidiabetics/
insulin, medication with a narrow therapeutic range
10 The drug is present on patients’ medication list at hospital 
admission
Non-adherence 11 No comparison with objective data24
Earlier experience of adverse drug reactions 12–16 Negative total score in both—the statements 12–16 and the 
Beliefs about Medicines Questionnaire (BMQ)25 or a positive 
total score in both—the statements 12–16 and the BMQ25
Missing information, partial knowledge of the patient, 
the patient does not understand the goal of the 
therapy
17 No comparison with objective data
Impaired manual skills—causing handling difficulties 18 No comparison with objective data
Visual impairment/impaired eyesight 18 No comparison with objective data
Difficult to handle medication 19 Medicines for parenteral, transdermal or inhalative 
application at time of hospital admission
GFR, glomerular filtration rate. 
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of DART in order to see if the questionnaire was easy 
to understand and not too intrusive. Furthermore, the 
investigator interviewed the patient in detail with regard 
to the patient’s attitude towards health and medicine. 
Validated questionnaires were used to investigate 
concerns and beliefs towards medicines (BMQ25) and 
mental health (Micro-Mental Test (MMT)26). Participa-
tion in the study was voluntary, the investigators offered 
no inducement or payment for subjects to participate. 
The patient was allowed to terminate the interview at 
any time without stating a reason.
Pretest
With a first draft of DART, we conducted a pretest with 
five inpatients. The procedure followed the same study 
flow we determined for the validation study (see the Study 
flow section). This pretest with inpatients served as an 
opportunity to correct any remaining issues of compre-
hensibility or ambiguity.
Data collection and analysis
All data were processed anonymously. In order to ensure 
traceability, we assigned each patient a unique identi-
fying number coding for the particular hospital/ward/
investigator/patient.
We used IBM SPSS Statistics Software, V.22 for data 
analysis. We evaluated sensitivity, specificity and prev-
alence of each question of DART by comparing the 
subjective answers in DART with objective data from 
medical records (diagnosis, laboratory values and medi-
cines at entry) and answers from the BMQ25 and the 
MMT.26 Acceptance criteria for correlation of subjective 
and objective data were defined a priori (cf. table 1). In 
addition we calculated the negative and positive predic-
tive values for each question in DART. Missing data were 
excluded from analysis.
Revision of statements
Statements with an unsatisfactory performance within 
reliability testing of the questionnaire (ie, sensi-
tivity <0.5 and possible poor patient understanding) 
were revised in their wording. In order to find a termi-
nology patients may be familiar with, we used official 
patient information leaflets (PILs) of selected drugs, 
which are either contraindicated or in need of a dose 
adaptation in presence of the risk factor assessed by 
the statement under revision. These PILs are contained 
in the official packages of the medicines, are created 
by the manufacturer and are bound to the Swiss legal 
requirements concerning readability and understand-
ability. We extracted and analysed the wording from 
these PILs which is used to describe the risk factor to 
patients and phrased new statements. We retested the 
new statements with the same study flow. In this cycle, 
we only recruited patients presenting one or more 
of the risk factors assessed by the statements under 
revision.
results
Development of the questionnaire
The first page of DART consists of items concerning 
the presence of diseases and high-risk medicines. The 
second page includes items reflecting the patient’s atti-
tude towards his/her medicines and statements about 
medication management and handling difficulties. The 
10 non-patient participants from the amateur test had no 
difficulties completing the questionnaire, and only minor 
adjustments in wording were necessary.
Validation of the questionnaire
The pretest with five inpatients did not reveal any addi-
tional issues.
During ward visits, we approached 208 eligible patients. 
One hundred and sixty-five (79.3%) consented to partic-
ipate, and we were able to complete 164 patient inter-
views (cf. figure 2). The median age was 74 years (range 
20–95) and 49% of participants were women. The mean 
number of drugs per patient at time of admission was 4 
and ranged from 0 to 19. Fifty-six patients (34%) came 
from the geriatric ward with a mean age of 81 (40–95) 
years and a mean number of drugs of 5 (0–19). Sixty-eight 
patients (42%) were from the medical ward with a mean 
age of 65 (20–91) years and a mean number of drugs of 3 
(0–15) and 40 patients (24%) were orthopaedic patients 
with a median age of 67.5 (20–91) years and a mean 
number of drugs of 4 (0–10).
After 51 interviews, we reduced the number of ques-
tions. We eliminated the questions about feasibility and 
understandability of DART, because we had enough 
meaningful data with a clear conclusion. For the same 
reason, we stopped answering the BMQ questionnaire 
that we used for comparison with the answers from DART. 
This allowed us to shorten the duration of the patient 
interview.
On average, it took patients 7 min to complete DART by 
themselves. None of the patients experienced any of the 
statements as bothersome or too intrusive on his privacy. 
Ten out of 51 patients (19.6%) showed some difficul-
ties in completing the questionnaire, 7 (13.7%) did not 
understand the wording of a statement and in three cases 
we had no clear statements what the difficulties were.
DART questions of the version V.1.0 reached speci-
ficity values from 27% to 100% and sensitivity values 
from 21% to 100%. Positive predictive values varied 
between 26% and 100% and negative predictive value 
varied between 20% and 100%. Regarding the intake 
of over-the-counter (OTC) drugs, 85 patients (35%) 
affirmed, 103 patients (63%) denied and 3 patients 
(2%) gave no answer. On the question ‘I feel well 
informed about my medication’, 85 patients (52%) 
answered with ‘strongly agree’, 45 (27%) agreed, 
18 (11%) disagreed, 3 (2%) strongly disagreed and 
13 patients (8%) gave no answer. Ten patients (6%) 
named difficulties with tablet splitting, 17 (10%) 
mentioned swallowing difficulties, 5 patients (3%) 
affirmed difficulties with visual recognition and 122 
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(74%) stated no such difficulties. Fifteen answers 
(9%) were missing. One hundred and twenty-five 
patients (74%) managed their medication by them-
selves, 12 (7%) had a relative or a friend who did the 
management, 15 patients (9%) named a home care 
person as their medication manager and 16 patients 
(10%) gave no answer. Sixteen patients (10%) indi-
cated the use of an inhaler, 15 (9%) the use of a trans-
dermal therapeutic system and 18 (12%) the use of 
a syringe for self-injection. One hundred and one 
patients (62%) did not use any of these application 
forms and 20 (12%) gave no answer.
Figure 2 Flow chart of the validation study. DART, Drug-Associated Risk Tool.
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revision of statements
Initially, statements about heart insufficiency, renal 
impairment and liver impairment showed low sensitivity 
(0.43, 0.28 and 0.33, respectively) due to possibly poor 
patient understanding. The PILs of in total 134 medi-
cines, either contraindicated or in need of dose adapta-
tion in presence of heart insufficiency, renal impairment 
or liver impairment, were used to identify expressions 
most frequently used to describe these conditions to 
patients. For DART V.2.0, the statements were changed 
accordingly: ‘I am suffering from a chronic renal disease’ 
was changed to ‘I have a restricted kidney function/
kidney dysfunction/kidney disease’, ‘I am suffering 
from a chronic cardiac disease’ was changed to ‘I have a 
heart weakness/heart performance weakness’ and ‘I am 
suffering from a chronic hepatic disease’ was changed 
to ‘I have a liver disease/liver dysfunction’ (cf. figure 3). 
These expressions were directly translated from German 
to English and may be written differently in English-
speaking countries.
A total of 31 patients (median age: 82 years (range 
59–96 years), 61% women), each presenting heart insuf-
ficiency, renal impairment or liver impairment as comor-
bidity, filled out the revised questionnaire (cf. figure 2).
After the second comparison to medical records, the 
sensitivity of the reworded item ‘heart failure’ improved 
from 0.43 to 0.80, while the specificity dropped from 
0.96 to 0.60. Similarly, the sensitivity for ‘renal insuffi-
ciency’ ameliorated from 0.28 to 0.38, while the spec-
ificity was lowered from 0.98 to 0.80. The small sample 
size combined with the low prevalence of liver insuffi-
ciency prohibited the evaluation of the refined statement 
covering liver insufficiency. With these modifications 
DART V.2.0 reached an overall sensitivity of 67% with an 
overall specificity of 88% (cf. table 2).
DIsCussIOn
We intended to create an easy-to-use and reliable screening 
tool to identify patients who are at increased risk for 
DRPs. The application of such a tool has the potential to 
support the healthcare professionals in choosing patients 
who benefit the most of intensified pharmaceutical care. 
A patient self-assessment tool may save time and resources 
of caregivers, but also allows the better involvement of 
the patient. Assessing DRPs with such involvement of the 
patient may reveal more issues.27
Figure 3 Drug-Associated Risk Tool (DART). Drug names mentioned in the section ‘My medicine’ correspond to the most 
commonly used medicines in the respective therapeutic class from the Swiss market.
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We used risk factors for the development of DART, 
previously identified in a combination of a literature 
search and an expert panel.23 To our knowledge, this 
approach has not been adopted previously in this area of 
research.
DART V.1.0 showed good acceptability and feasibility. 
The patients were able to complete the self-assessment 
within on average 7 min and indicated no major difficul-
ties with understanding the content of the questionnaire. 
The 48 patients (23%) who refused to participate were 
either not interested in participating or felt too tired to 
follow an interview.
After the validation of the first version of DART (V.1.0), 
we engaged three statements with an identified low sensi-
tivity and possible poor patient understanding and aimed 
to improve their wording by implementing expressions 
into our questionnaire which are frequently used in PILs. 
We were able to include a statement covering heart failure 
with an acceptable sensitivity, while observing some more 
false positive answers. The reliability of patients to answer 
questions about renal insufficiency remains a challenge: 
Disease awareness among patients with chronic kidney 
disease is generally low,24 28 29 hence making it difficult 
to retrieve information on from a self-assessment ques-
tionnaire. The low knowledge of chronic comorbidities 
like chronic kidney disease may show a lack of patient 
education within counselling and may therefore pose an 
additional task for pharmaceutical care.
Finally, after the validation of the revised questionnaire, 
most statements of DART V.2.0 showed high specificity 
(mean value 88%, range 27%–100%) preventing false 
positive answers with a high probability. The sensitivity 
of the statements was lower and showed higher vari-
ability (mean value 67%, range 21%–100%). The sensi-
tivity turned out to be higher in statements addressing 
conditions that require regular disease control and daily 
attention to self-care and drug management. Drugs 
requiring a high level of self-management showed the 
highest sensitivity (eg, oral anticoagulants, insulin and 
oral antidiabetics).
Several factors may have influenced the sensitivity 
values. First, the defined criteria for correlation (cf. 
table 1) served as a basis for the validation of the ques-
tionnaire. Depending on how we defined the criteria, we 
reached a certain degree of correlation between patients’ 
answers and the objective data.  Second, we evaluated the 
sensitivity and specificity of each question by comparing 
the subjective answers in DART with objective data from 
medical records. Literature shows that medication histo-
ries at the time of admission are often erroneous and 
incomplete,30 which might have influenced our results. 
Especially the statement ‘I take more than 5 drugs every 
day, prescribed by my physician’, showed surprisingly 
weak correlation between subjective patient answers and 
objective medical data. Lau et al31 stated that regarding 
at the medication history in the hospital medical record, 
25% of the prescription drugs in use are not recorded and 
61% of all patients have one or more drugs not registered. 
Bedell et al32 evaluated the discrepancies between what 
physicians prescribe and what patients report they 
actually take. They showed that discrepancies between 
recorded and reported medication are common. Half of 
the discrepancies (51%) result from patients taking medi-
cations that were not recorded. One-third of the discrep-
ancies involved OTC drugs or herbal therapies. We used 
medical records as reference for testing our statements’ 
and the patients’ reliability to provide correct answers 
in our self-assessment questionnaire. Errors within the 
medical histories as described above would carry over to 
our findings about the statements. Third, patients stated 
that they had no problems with filling in DART; however, 
we noticed some problems with their understanding of 
the word ‘chronic’. And we were aware of the possible 
existence of a social desirability bias when we directly 
asked patients for their opinion about the questionnaire.
Finally, the low prevalence of some risk factors (eg, 
antiepileptic drugs, tricyclic antidepressants, digoxin and 
anticholinergic drugs) hinders clear conclusions about 
the validity of the respective statements in DART.
COnClusIOns
The self-assessment questionnaire ‘DART’ showed a satis-
fying feasibility and reliability. Despite some low sensi-
tivity values, this questionnaire seems to be applicable 
to patients in a hospital setting. Patients may be a valu-
able, but often neglected source of information. Asking 
them about their conditions, their medicines and related 
concerns and problems may facilitate getting a first, but 
broad picture of the risk for DRPs and possible pharma-
ceutical needs. Compared with gathering all the relevant 
data from case notes, electronic patient files and other 
sources, a self-assessment questionnaire seems to be a 
quick and easy method to identify patients in need for 
intensified pharmaceutical care.
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